CVS Health study highlights GLP-1 benefits and the affordability challenge
PR Newswire•15/11/2026•10:00 ET
6
Key Highlights
- ➤GLP-1 use linked to better outcomes, lower hospital use and lower medical spending
- ➤Current pharmacy prices exceed observed medical savings across the study population
- ➤Approximately $350 monthly net price would balance spending over three years
- ➤More than 137 million U.S. adults medically eligible for semaglutide across indications
Expert Statements
Amy Compton-Phillips, M.D.
“GLP-1s are remarkably effective medicines, and the health benefits are real. The challenge is making those benefits affordable at scale.”
Amy Compton-Phillips, M.D.
“That means getting treatment to the people most likely to benefit, helping them stay on therapy and bringing the price to a level that supports broader access.”
CVS Health study highlights GLP-1 benefits and the affordability challenge PR Newswire
Real-world analysis finds better outcomes and lower medical spending, but current prices limit the full economic value
Get started
Create a free account to read the full story.
